Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)
ESMO 2021: FRAME Trial
Share.
About Author
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
